Radius Health and Menarini Group Report Positive Phase 3 Results from EMERALD Trial
Radius Health, Inc. (NASDAQ: RDUS) and The Menarini Group have reported positive topline results from EMERALD Trial Evaluating Elacestrant in Breast Cancer. EMERALD has met both primary endpoints of the trial. “We are extremely excited as elacestrant is the first...